Obermatt
See Similar Stocks →

Neuren Pharmaceuticals

ASX:NEU · NZNEUE0001S8
PharmaceuticalsSmall

360

29
Medium confidence — indicative
EV / EBIT1
Price / Owner Earnings14
Owner Earnings Yield51
Dividend Yield77
Price/Sales10
EV / Gross Profit3
Price/Book19
Return on Capital51
Cash Return on Capital67
Return on Equity60
EBIT Margin98
Gross Profitability19
Cash Conversion90
Accruals62
Owner Earnings Margin91
Sales growth40
Profit Growth36
Long-Term EPS Growth18
Owner Earnings Growth19
Reinvestment1
Price momentum66
Debt load67
Refinancing34
Debt Payback100
Liquidity—
Analyst ratings70
Opinion Changes50
Price Target Upside70
Market mood94
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Neuren Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryAustralia
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeASX
Founded2001
Employees22
Websiteneurenpharma.com
ISINNZNEUE0001S8
Last UpdateApr 2, 2026
Indices
ASX 200 (Australia)ASX 300 (Australia)
Themes
PsychiatryNeurologyNeuroscienceCentral Nervous SystemBiopharmaBiotechnologyTherapeutics

Description

Neuren Pharmaceuticals Limited is a publicly listed biopharmaceutical company developing drugs for neurological disorders. The company's primary focus is on developing innovative therapies that address significant unmet medical needs in the field of…

Analysis

Beloved champion

Neuren Pharmaceuticals Limited is a beloved champion: its quality is genuine, and the market already prices it as exceptional.

The price is expensive. You pay 58.1× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is tepid and the balance sheet is uncertain. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Neuren Pharmaceuticals with its peers
Clarity Pharmaceuticals
ASX:CU6
8
CountryAustralia
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Pharmicell
KSC:005690
35
CountrySouth Korea
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
U-BX Technology
NAQ:UBXG
27
CountryChina
IndustryIT Services
SizeSmall
Full Stock Analysis →
Samsung Pharm
KSC:001360
—
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Prenetics Global
NMQ:PRE
52
CountryHong Kong SAR China
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
Lottery Corporation
ASX:TLC
49
CountryAustralia
IndustryHotels, Restaurants & Leisure
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →